Diederik F.S. Kehrer

Author

Rotterdam University of Applied Sciences

Also Known As

D F Kehrer, D F S Kehrer, D. F. Kehrer, D. F.S. Kehrer, D. Kehrer, D.F.S. Kehrer, Diederik F S Kehrer, Diederik F. S. Kehrer, Diederik F.S. Kehrer, Diederik FS Kehrer

Publications

Citations

H-Index

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus MC Cancer Institute Sint Franciscus Gasthuis Erasmus MC IJsselland Ziekenhuis

About

Diederik F.S. Kehrer is an author at Rotterdam University of Applied Sciences specializing in medicine, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	651
2	Biochemistry	2	2	83
3	Cell Biology	2	2	98
4	Health Sciences	1	1	45
5	Endocrinology	1	1	157

Diederik F.S. Kehrer

Publications

916

Citations

H-Index

Page 1

	Year	Citations
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Diederik F.S. Kehrer, Alex Sparreboom, Jaap Verweij, PubMed Gastrointestinal PharmacologyGastroenterologyPathologyPharmacotherapyAntimicrobial Chemotherapy	2001	175
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer, The Lancet Oncology MedicineClinical TrialsGynecologyBreast CancerAromatase	2017	157
Modulation of Irinotecan Metabolism by Ketoconazole Diederik F.S. Kehrer, Ron H.J. Mathijssen, Jaap Verweij, Journal of Clinical Oncology	2002	120
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings Stefan Kubicka, Richard Greil, Thierry André, Annals of Oncology Gastrointestinal OncologyMedicinePathologyColorectal CancerMetastatic Colorectal Cancer	2013	101
Prophylaxis of Irinotecan-Induced Diarrhea with Neomycin and Potential Role for <b> <i>UGT1A1*28</i> </b> Genotype Screening: A Double-Blind, Randomized, Placebo-Controlled Study Floris A. de Jong, Diederik F.S. Kehrer, Ron H.J. Mathijssen, The Oncologist	2006	88
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Diederik F.S. Kehrer, Wataru Yamamoto, Jaco J. Verweij, PubMed Molecular PharmacologyBiochemistryExperimental StudiesPharmacologyTerminal Disposition Phase	2000	61
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients Bianca Mostert, Anieta M. Sieuwerts, Jaco Kraan, Annals of Oncology Breast OncologyOncologyMedicineCancer GenomicsTumor Cells	2014	53
Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer Wendy Onstenk, Anieta M. Sieuwerts, Marleen Weekhout, Cancer Letters Metastatic Breast CancerBreast OncologyTumor HeterogeneityMedicineCancer Genomics	2015	45
Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity Diederik F.S. Kehrer Journal of Clinical Oncology	2002	41
Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism Peter de Bruijn, Diederik F.S. Kehrer, Jaap Verweij, Journal of Chromatography B Biomedical Sciences and Applications Liquid Chromatographic DeterminationPharmaceutical ScienceBiochemistryPotent InhibitorMedicine	2001	22

Page 1